Exploring how dissection depth affects scar formation in early gastric cancer treatment

The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma

NA · Second Affiliated Hospital, School of Medicine, Zhejiang University · NCT05323929

This study is testing how the depth of a specific surgery for early gastric cancer affects scar size and healing in patients.

Quick facts

PhaseNA
Study typeInterventional
Enrollment200 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University (other)
Locations1 site (Hangzhou, Zhejiang)
Trial IDNCT05323929 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the relationship between the depth of endoscopic submucosal dissection (ESD) and the resulting scar formation in patients with early gastric cancer. It is a single-center, prospective, group-controlled study that aims to compare scar sizes resulting from different dissection depths and assess their impact on gastric function and patient prognosis. The findings are intended to provide evidence-based guidelines for ESD treatment in early gastric cancer, ultimately leading to improved clinical techniques and patient outcomes.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 to 75 with early gastric cancer that meets specific criteria regarding tumor size and differentiation.

Not a fit: Patients with advanced gastric cancer or those with larger lesions that exceed the specified size limits will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more effective treatment strategies for early gastric cancer, improving patient prognosis and quality of life.

How similar studies have performed: While this study explores a specific relationship in gastric cancer treatment, similar approaches in other cancers have shown promise, indicating potential for success.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients older than 18 years old and younger than 75 years old.
* Early gastric cancer (T1a stage) diagnosed by gastroscopy or ultrasonography, differentiated and no ulcer; or early gastric cancer (T1a stage), differentiated with ulcer, lesion diameter \<3cm; or early gastric cancer (T1a stage), undifferentiated and No ulcer, lesion diameter \<2cm.
* Pathological diagnosis of gastric cancer.
* No further treatment is required.
* Patients diagnosed for the first time without other serious gastrointestinal diseases.

Exclusion Criteria:

* Those who did not comply with the test requirements, obviously violated this protocol, or switched to other protocols in the middle of treatment.
* Advanced gastric cancer; or undifferentiated gastric cancer lesions \> 2 cm in diameter; or differentiated gastric cancer with ulcer lesions \> 3 cm in diameter.
* Coagulation disorders.
* Serious heart, liver, kidney and other diseases, can not tolerate ESD treatment.
* Patients with gastric cancer complications such as gastrointestinal bleeding and perforation that need emergency treatment.
* Patients with distant metastasis.
* Patients with other tumors, patients with a history of malignant tumors (except early carcinoma in situ.
* The patient himself requests to withdraw from the trial.
* The researcher believes that the patient is not suitable to participate in this study.

Where this trial is running

Hangzhou, Zhejiang

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Early Gastric Cancer, Endoscopic Submucosal Dissection

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.